Approved Biologic and Biosimilar TNF-α Inhibitors and their therapeutic indications: Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Adult Crohn’s Disease (ACD), Pediatric Crohn’s Disease (PCD), Ulcerative Colitis (UC), Pediatric Ulcerative Colitis (PUC), Plaque Psoriasis (Ps), Hidradenitis Suppurativa (HS) and Uveitis (UV). This evidence concerns the gene TNF and ankylosing spondylitis.